

ProstaLund signs new agreement with existing customer

ProstaLund and Urogyn Sverige AB have signed a new agreement regarding disposables for CoreTherm® treatments. The new agreement guarantees revenues of about SEK 1.6 million over the next twelve months. The first delivery under the new agreement will take place in May.

ProstaLund and Urogyn Sverige AB have today signed a new agreement regarding disposables used in CoreTherm® treatments. The agreement extends over twelve months, with an option to extend. The order value is SEK 1.6 million during the contract period. The agreement replaces the previous agreement with Urogyn Sverige AB. Previous agreement were worth about SEK 0.9 million per year.

"This is the second agreement with significantly increased guaranteed volumes we sign within a month. The fact that we are now entering into yet another agreement with a clinic that wants to scale up its CoreTherm® business means that we are taking a much stronger grip on the BPH/BPE market in Sweden and especially the Stockholm area. Both new agreements prove that CoreTherm® delivers good results to patients. For ProstaLund, the agreements mean that we will have continuity in terms of both orders and cash flow, which means that we can continue our pace of expansion according to plan", says CEO Johan Wennerholm in a comment.

For further information, please contact:

Johan Wennerholm, CEO Tel. +46 (0) 730 429997 Email: johan.wennerholm@prostalund.com

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB Phone: +46 40 200 250 E-mail: ca@vhcorp.se PRESS RELEASE 10 May 2022 15:40:00 CEST



This information is information that ProstaLund AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-05-10 15:40 CEST.

Attachments

ProstaLund signs new agreement with existing customer